Company: OFIX
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0000950170-25-061062
Chunk: 38

Company: Orthofix Medical Inc.
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 38
---
-based restricted stock units, and 25% performance-based stock options. Mr. Calafiore also received sign-on equity incentive awards of $3,500,000, delivered via a mix of 50% performance-based restricted stock units, 25% time-based restricted stock units, and 25% performance-based stock options. The Committee’s approval of Mr. Calafiore’s sign-on award and annual long-term incentives reflected his experience as a Chief Executive Officer, his willingness to relocate from Italy to the Company’s U.S. headquarters, and competing opportunities potentially available to him, both within and outside of the U.S., as his then-current employer was being acquired.

Ms. Andrews was appointed as the Company’s Chief Financial Officer effective January 15, 2024. Ms. Andrews’ offer compensation included an annual base salary of $475,000, a target bonus of 70% of salary, and target long-term incentives of $1,800,000, delivered via a mix of 50% performance-based restricted stock units, 25% time-based restricted stock units, and 25% performance-based stock options. The Committee’s approval of Ms. Andrews’ sign-on award reflected her prior experience as a Chief Financial Officer of a similarly situated Nasdaq-listed company, and competing opportunities potentially available to her.

Mr. Cedrón was appointed as the Company’s Chief Legal Officer effective April 15, 2024. Mr. Cedrón’s offer compensation included an annual base salary of $470,000, a target bonus of 70% of salary, and target long-term incentives of $1,500,000, delivered via a mix of 50% performance-based restricted stock units, 25% time-based restricted stock units, and 25% performance-based stock options. The Committee’s approval of the sign-on award reflected that Mr. Cedrón would leave his senior leadership role at another life sciences company, where he was receiving, and expected to continue to receive, competing long-term incentives.

Mr. Reinhardt was appointed as the Company’s President, Global Spine effective June 10, 2024. Mr. Reinhardt’s offer compensation included an annual base salary of $480,000, a target bonus of 70% of salary, and target long-term incentives of $1,690,000, delivered via a mix of approximately 56% three-year cliff-vesting stock options, 22% performance-based restricted stock units, 11% time-based restricted stock units, and